Multidrug resistance of Mycobacterium tuberculosis is declared a serious global threat by the World Health Organization. Our project aims at developing a comprehensive model of molecular mechanisms responsible for antimicrobial drug resistance of tuberculosis. Isoniazid is the main drug used for TB treatment, because it interacts with the bacterial catalase that leads to the bacterial death. The library of isoniazid resistant strains (over 100 different strains) will be used as experimental basis for building theoretical and computational models of the molecular processes leading to drug resistance of mutated bacteria. The model will be used for suggesting effective treatment targeting these mechanisms and overcoming the resistance. AMR-TB RISE will be used to utilise the expertise of highly specialised research groups of biologists, clinicians, biochemists, physicists, computer engineers, and mathematicians allowing the researches from these groups to work in multiple laboratories of the Consortium all over the world. Particular attention will be given to training the next generation of young researcher and forming tightly interconnected, long term collaboration devoted to solving the pressing global problem of antimicrobial resistance not only in TB, but in a wide spectrum of diseases.